Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | YAP1 | P46937 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747164 | 0.91 | KDM4A (0.57) | PPARGMAPT | |
| SCHEMBL8387599 | 0.87 | BCL2 (0.56) | PPARGCTSLYAP1 | |
| SCHEMBL10445399 | 0.86 | CTSL (0.65) | CTSLMAPTMEN1KMT2A | |
| SCHEMBL1309025 | 0.86 | GAA (0.50) | MAPTGAARAB9AMEN1KMT2A | |
| SCHEMBL10445398 | 0.86 | CTSL (0.65) | CTSLMAPTMEN1KMT2A | |
| SCHEMBL1309029 | 0.86 | GAA (0.50) | MAPTGAARAB9AMEN1KMT2A | |
| SCHEMBL4934272 | 0.85 | BCL2 (0.53) | PPARGYAP1MAOB | |
| SCHEMBL10201897 | 0.85 | CTSL (0.46) | CTSLMAPTRAB9AMEN1KMT2A | |
| SCHEMBL19867063 | 0.84 | ITGA4 (0.51) | CTSLMEN1KMT2A | |
| SCHEMBL16552342 | 0.84 | PPARG (0.69) | PPARGLTA4HYAP1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | PPARG 3995/4885CTSL 4621/4885LTA4H 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.